EFA vs XBI
iShares MSCI EAFE ETF vs SPDR S&P Biotech ETF
- • EFA has the lower expense ratio at 0.32% vs 0.35% for XBI.
- • EFA pays a higher dividend yield (3.26%).
Side-by-side metrics
| Metric | EFA | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.32% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.26% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $76.62B | $10.92B |
YTD return | 11.02% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.86 | 1.01 |
P/E ratio | 17.37 | — |
Last price | $104.61 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
EFA top holdings
| ASML.AS | ASML Holding NV | 2.86% |
| ROP.SW | Roche Holding AG Ordinary Shares new | 1.60% |
| SHEL.L | Shell PLC | 1.46% |
| NOVN.SW | Novartis AG Registered Shares | 1.39% |
| HSBA.L | HSBC Holdings PLC | 1.37% |
| AZN.L | AstraZeneca PLC | 1.32% |
| NESN.SW | Nestle SA | 1.24% |
| SAP.DE | SAP SE | 1.11% |
| 8306.T | Mitsubishi UFJ Financial Group Inc | 1.09% |
| SIE.DE | Siemens AG | 1.00% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About EFA
EFA (iShares MSCI EAFE ETF) is Developed-market equities outside US/Canada. Managed by iShares, the fund carries $76.6B in assets under management, an expense ratio of 0.32%, a dividend yield of 3.26%. Its largest holding is ASML Holding NV (ASML.AS), which represents 2.9% of the portfolio. Real Estate is the fund's largest sector exposure at 1.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.